NCT07344844Recruiting
Adaptive Stereotactic Radiotherapy for Localized Prostate Cancer
Intérêt de la radiothérapie Adaptative en stéréotaxie Prostatique
Source: ClinicalTrials.gov · Last updated 15 Jan 2026
Brief summary (registry, in English)
This study evaluates whether adaptive stereotactic body radiotherapy (SBRT) provides dosimetric advantages compared to non-adaptive SBRT in localized prostate cancer. Five low-dose CT scans are performed before each SBRT session to assess anatomical variations (bladder filling, rectal volume) and determine if a dosimetric recalculation would have been required. The study also evaluates cumulative dose to organs at risk, patient-reported quality of life over 24 months, and overall and recurrence-free survival.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 15 Dec 2025
- Start date
- 18 Nov 2025
- Primary completion date
- 1 Mar 2029
- Lead sponsor
- Clinique Sainte Clotilde
- Diseases
- Prostate cancer
- NCT number
- NCT07344844
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 18 Nov 2025 to the primary completion date, 1 Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of urological (prostate) or digestive surgery that could influence study outcomes
Other
- Unable to read, write, or understand French
- Vulnerable patient as defined by Article L1121-6 of the French Public Health Code
- Adult under guardianship, curatorship, or legal protection ("sauvegarde de justice")
- Patient unable to personally provide informed consent according to Article L1121-8 of the French Public Health Code
- Patient already included in another interventional study that could interfere with study outcomes
- Refusal to sign the written informed consent form
Who the study is looking for
- Male aged ≥60 years
- Localized prostate cancer of low or intermediate risk (T1-T2)
- Gleason score 6-7
- PSA \<15 ng/mL
- No evidence of metastatic disease
- Radiotherapy indicated for prostate cancer
- Affiliated with or benefiting from a French social security system
- French-speaking patient
- Patient appropriately informed and having signed a written informed consent form
Age in the registry: 60 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Clinique Sainte Clotilde Coordinator of this site? Confirm its status | Saint-Denis | Réunion | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.